Renal Cell Carcinoma (First-Line Advanced/Metastatic) | Decision Base | US | 2015
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers?
Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the treatment of advanced/metastatic renal cell carcinoma (RCC) in the first line. While mTOR inhibitors such as temsirolimus (Pfizer’s Torisel) have expanded the treatment options for patients in this setting, especially those with poor-prognosis disease, RCC remains incurable, and most first-line patients relapse following treatment. Significant clinical and commercial opportunities remain for new therapies that can provide greater survival benefits than the currently available agents.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
